About

About TAHO Pharmaceuticals Ltd. AHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation. About TAHO Pharmaceuticals Ltd. About TAHO Pharmaceuticals AHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation. TAHO Pharmaceuticals, founded in 2010 in Taipei, Taiwan, and listed on the Taipei Exchange, is dedicated to transforming drug delivery with heart and innovation. We specialize in advanced formulations that make oral and injectable medications safer, more effective, and easier to use. Our mission is to enhance patient lives with thoughtful, next-generation solutions for diverse needs, especially those struggling with traditional treatments. Our success stems from our proprietary Transepithelial Delivery System (TDS) platform. It features: Transdermal Delivery: Patches provide steady medication through the skin, eliminating injections or frequent dosing—ideal for chronic care. Transmucosal Delivery: Oral thin films ensure rapid onset, enhanced bioavailability, and improved experience via the mucosa. We’re not merely creating new delivery methods—we are redefining the future of healthcare with compassion, ensuring our innovations bring hope and comfort to patients and caregivers. TAHO Pharmaceuticals Ltd., founded in 2010 and headquartered in Taipei, Taiwan, is a publicly listed company on the Taipei Exchange. The company focuses on advancing drug delivery through innovative formulation technologies that improve the safety, efficacy, and convenience of existing medications. Leveraging its proprietary Transepithelial Delivery System (TDS) platform, TAHO develops transdermal and transmucosal drug delivery solutions designed to enable efficient drug absorption, improve patient compliance, and optimize therapeutic outcomes. By creating patient-friendly alternatives to traditional oral and injectable medications, TAHO is committed to addressing unmet medical needs and improving quality of life for patients worldwide. TAHO is an R&D-driven specialty pharma pioneering oral and transdermal drug-delivery systems. TAHO's Transepithelial Delivery System enables the development of oral dissolving films and transdermal patches for anticoagulants and many other treatments